Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hemophagocytic syndrome].

A Karras1, O Hermine

  • 1Service de néphrologie et de transplantation rénale, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France. alexandre.karras@sls.ap-hop-paris.fr

La Revue De Medecine Interne
|October 16, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics and outcomes of patients with pediatric-onset non-mastocytosis mast cell activation disorders: A CEREMAST study.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2026
Same author

Ibrutinib-induced spontaneous penile hematoma.

Annales de dermatologie et de venereologie·2025
Same author

KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis.

The journal of allergy and clinical immunology. In practice·2025
Same author

Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

A high prevalence of hereditary alpha-tryptasemia in pediatric mastocytoma.

Allergy·2024
Same author

Pregnancy outcome in patients with a medical history of immunoglobulin A vasculitis: a case-control study.

Scandinavian journal of rheumatology·2023
Same journal

[Atypical low back pain].

La Revue de medecine interne·2026
Same journal

[Polycythemia associated chronic haemolysis].

La Revue de medecine interne·2026
Same journal

[Persistent headaches in a 55 year-old man].

La Revue de medecine interne·2026
Same journal

[Abdominal pain, fever and arthralgia in a 49-year-old woman].

La Revue de medecine interne·2026
Same journal

[Cardiorespiratory functional disorders: A transnosologic approach].

La Revue de medecine interne·2026
Same journal

[Diagnostic evaluation for suspected polycythemia].

La Revue de medecine interne·2026
See all related articles

Hemophagocytic syndrome, a severe condition involving macrophage overstimulation, presents with diverse symptoms and poor prognosis. Advances in understanding T cell and TNF-alpha roles offer hope for improved treatments.

Area of Science:

  • Immunology
  • Hematology
  • Pathology

Context:

  • Hemophagocytic syndrome (HPS) involves inappropriate macrophage activation, leading to blood cell destruction and cytokine release.
  • Clinical signs include fever, organomegaly, and cytopenias; diagnosis relies on bone marrow examination.
  • HPS can be primary (pediatric) or secondary to infections, autoimmune diseases, or lymphomas, with a 50% mortality rate.

Purpose:

  • To review the pathogenesis, diagnosis, and treatment of hemophagocytic syndrome.
  • To highlight recent advances in understanding the role of T lymphocytes and TNF-alpha.
  • To discuss current and future therapeutic strategies for HPS.

Summary:

  • HPS is characterized by cytokine storm and hemophagocytosis, presenting with non-specific symptoms and laboratory abnormalities.

Related Experiment Videos

  • Genetic studies reveal T lymphocyte and TNF-alpha's critical role in HPS pathogenesis, particularly in familial cases.
  • Allogeneic bone marrow transplantation has significantly improved survival in pediatric HPS.

    • Impact:

    • Understanding HPS pathogenesis is crucial for developing targeted therapies.
    • New treatments may focus on specific mediators like TNF-alpha.
    • Prospective trials are needed to optimize treatment for secondary HPS forms.